Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Myokardia IncfiledCriticalMyokardia Inc
Priority claimed from PCT/US2014/043192external-prioritypatent/WO2014205223A1/en
Publication of MA38789A1publicationCriticalpatent/MA38789A1/en
Publication of MA38789B1publicationCriticalpatent/MA38789B1/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
Cette invention concerne de nouveaux composés de pyrimidine-dione et des sels pharmaceutiquement acceptables de ceux-ci, qui sont utiles dans le traitement de la cardiomyopathie hypertrophique (hcm) et les affections associées à l'hypertrophie ventriculaire gauche ou à la dysfonction diastolique. La synthèse et la caractérisation des composés et de leurs sels pharmaceutiquement acceptables sont en outre décrites ainsi que des méthodes pour traiter la hcm et autres formes de maladie cardiaque.This invention relates to novel pyrimidine dione compounds and pharmaceutically acceptable salts thereof, which are useful in the treatment of hypertrophic cardiomyopathy (hcm) and conditions associated with left ventricular hypertrophy or diastolic dysfunction. The synthesis and characterization of the compounds and their pharmaceutically acceptable salts are further described as well as methods for treating hcm and other forms of heart disease.
MA38789A2013-06-212014-06-19
Pyrimidine-dione compounds against heart disease
MA38789B1
(en)
Substituted azaindoline compounds which have an inhibitory activity of the apoptosis protein for their uses in the treatment and / or prophylaxis of cancer